End Stage Renal Disease Clinical Trial
Official title:
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest
problems in their hearts is that the muscle wall of the heart thickens. This makes it less
efficient. We found in patients with mild kidney disease that a drug normally used to treat
gout (allopurinol) had the remarkable side effect of being able to reduce this thickening of
their heart wall. In this new study we aim to find out if this benefit of allopurinol also
occurs in severe kidney patients i.e. those on regular dialysis. We also are trying to
figure out the best dose of allopurinol to use. To do this we are planning a study where we
will recruit patients with kidney disease who are on dialysis. The 1st phase of the trial
will be to determine the best dose of allopurinol to use and the second phase will be to do
a clinical trial where patients will be randomly allocated to either this optimum dose of
allopurinol or a dummy medication (placebo) and will receive one year of treatment. They
will have a special scan of the heart using an MRI machine to measure the extent of
thickening of their heart muscle before they start on treatment and will have a further MRI
scan when their one year treatment finishes.
Phase 1- the dose finding study, will involve 10 patients who will have between 3 and 7
visits to the hospital scheduled around 4 to 17 dialysis sessions. The later study will
involve up to 76 patients who will be asked to attend the hospital up to 8 times over a 13
month period.
The ALTERED trial is a randomised, double blinded, placebo controlled multi-centre study
conducted in NHS Tayside, NHS Ayrshire & Arran & NHS Greater Glasgow & Clyde to compare
allopurinol (dose to be confirmed from dose escalation study noted above) at either, 100mg,
200mg, 250mg, 300mg or 350mg to placebo.
Patients will be enrolled in this trial for a period of between 12 to 13 months.
At screening visit an initial history and clinical examination will be performed.
Participants will then undergo an echocardiogram to ensure no significant heart failure
unless they have had an ECHO in the previous 4 years..Should the participant be eligible for
the study they will have a Cardiac Magnetic Resonance Imaging (MRI) scan prior to their
baseline (Randomisation) visit. They will also have bloods taken for safety analysis, have a
12 lead ECG done, vital signs recorded and if they agree have 24 hour BP monitoring.
Once the patient is known to be eligible they will return - for the first randomisation,
dosing visit at any time up to four weeks after screening. At this randomisation visit post
dialysis session, eligible participants will be randomly assigned to either placebo or
allopurinol 100mg.
They will continue on allopurinol/placebo 100mg for 2 weeks, with dosing after each dialysis
session only. They can have FMD, PWV and PWA measurements taken. All participants will be
offered the opportunity to opt in or out of the FMD, PWV and PWA measurements, which are
secondary outcome measures only.
If study drugs are tolerated, the dose would be increased at weekly intervals after the
200mg dose to the allopurinol dose chosen by the dose escalation study, if greater than
200mg. Baseline blood samples will be taken for routine bloods including full blood count,
renal function, liver function, random blood glucose, haemoglobin A1C, lipids, calcium and
phosphate. These blood tests will be repeated at 6, 9 and 12 months. Routine safety bloods
(including U+Es and LFTs) will be taken pre-dialysis at visits throughout the study.
Subjects will be followed at baseline, week 2, week 6, month 6, month 9 and month 12.
Research bloods and urate levels will be taken at baseline, week 6, months 6, 9 and 12.
However, to ensure blinding throughout urate results will not be made available to the
investigators until the end of the trial. BP is recorded as part of standard care and will
be available for analysis. Pre and post-dialysis readings will be recorded. Other variables
such as weight and fluid removed during dialysis are also noted as part of routine care and
will be available for analysis. 24-hour BP will be performed at the start and end of the
study if participants agree. Cardiac MRI scans will be performed at the start and at the end
of the 12 month study period. Patients will continue with all their usual medication, which
will remain unchanged throughout unless clinically indicated.
CMRI Methods The MRIs will normally be done on a non dialysis day. If this is not possible
then we will rarely perform an MRI on a dialysis day. Baseline and repeat CMR examinations
in screening (between 0-6 weeks before randomisation) and after the final 12 month (+/- 6
weeks) visit will be performed on similar 3T Magnetom scanners (Siemens, Erlangen, Germany)
using dedicated phase array cardiac and phosphorous spectroscopy coils. Serial contiguous
short-axis cines will be acquired from the vertical long axis and horizontal long axis of
the left ventricle (electrocardiogram gated, steady-state free precession imaging [true fast
imaging with steady-state precession], with the short axis imaging parameters being a
repetition time of 2.5ms, echo time of 1.1ms, flip angle of 60°, and slice thickness 6mm).
Analysis will be performed offline (Argus Software, Siemens) by a single blinded observer
for the assessment of ventricular volumes (EDV, ESV, stroke volume), EF, and left
ventricular mass. This single observer will analyse scans from both sites. The
reproducibility of the left ventricular mass assessment using MRI will be derived for this
observer. A test-retest intraobserver coefficient of variation of 2.0% is usual in our past
MRI studies. We will also assess reproducibility between each site, although the same
observer will assess all scans at both sites. We will take the opportunity to measure other
MRI parameters of interest which are easily obtained with little extra scan time:
Phosphorous -31 MR spectroscopy, T1 mapping and aortic compliance by methods already
published by us.[29, 30] Both will give significant added value.
MR spectroscopy will see whether allopurinol increases high energy phosphates in ESRD
(measured by PCr:ATP) which it is likely to do since it is known to increase ATP levels in
vitro and it is now known to improve cardiac energetics (MRI measured) in human heart
failure.[31, 32] We will measure high energy phosphates (HEP), comparing Phosphocreatine :
Beta adenosine triphosphate (PCr:ATP) ratio from the long axis views of the left
ventricle.[29] In addition we will use MRI to assess aortic vascular compliance and pulse
wave velocity [30] using cine transverse thoracic aortic gated steady state free precession
acquisitions which will complement well the other peripheral vascular measures of
endothelial/vascular function being assessed (see below). Should a scanner at any site
become unavailable for a prolonged period of time during the study an alternative scanner
will be used. Throughout the study MRI methods will be adapted as appropriate to ensure
optimal study results can be obtained.
FMD FMD will be offered to all participants in the main trial, but may be declined without
affecting their participation in the main trial.
FMD on the brachial artery will be performed in the non-fistula arm on three visits
(baseline, month 9 and month 12) using a Philips iE33 ultrasound machine (Phillips Medical
Systems, United Kingdom) according to the guide-lines set by the International Brachial
Artery Reactivity Task Force.[33] The brachial artery will be longitudinally imaged above
the elbow using an 11.3-MHz probe. The image will be recorded for 2 minutes, followed by
induction of forearm ischaemia by inflating a cuff below the elbow to 200 mmHg (or 50 mmHg
above SBP, whichever is higher) for 5 minutes and deflating rapidly. The resulting reactive
hyperaemia will be recorded for a further 2 minutes. After a rest period, the procedure will
be repeated, with 0.4mg of glyceryl trinitrate being administered sublingually to determine
endothelium-independent dilation. FMD will be expressed as per cent change in diameter
relative to the baseline diameter at rest. Analysis of all FMDs will be performed on
Brachial Analyser software (Medical Imaging Applications, LLC) by a single trained
investigator (the clinical research fellow) to avoid inter-observer variability. This
investigator will be blind to allocated treatments. Our intra-observer coefficient of
variation for FMD is usually 5.2%. Two factors should ensure reliable results despite there
being two sites : each patient will always be studied on the same equipment and wherever
possible the same individual (the research fellow) will do all the tests and interpret them
(blindly) at both sites. For further reassurance, a selection of blinded ultrasound scans
will be re-analysed to ensure good reproducibility at each site and between sites.
Applanation Tonometry PWA will be offered to all participants in the main trial, but may be
declined without affecting their participation in the main trial.
Pulse wave analysis (PWA) and PWV will be determined in the non-fistula arm by recording the
radial waveforms and radial-carotid waveforms, respectively, at three visits (baseline,
month 9 and month 12) using the Sphygmocor system. The central AIx will be corrected to a
heart rate of 75 beats/min. Wherever possible, a single trained investigator (the clinical
research fellow) who is blind to the allocated treatment will perform the PWA and PWV at
both sites. We will also use bio-impedance at the same time to measure total body water in
MRIs done at Glasgow sites.[21] . This will complement the end diastolic volume data from
the MRI at both sites. In our index study, EDV fell but we did not know if this was due to
afterload reduction or to a global fall in body water.[21] Bio-impedance will help determine
this.
Research Blood tests Research bloods will be taken at baseline, week 6 and months 6, 9 and
12. Research bloods will include BNP, inflammatory markers and other markers of interest.
Additional markers may be tested on the samples at a later date. The total amount of
research blood taken at each visit will be no more than 30ml. We shall also seek consent for
future ethically approved genetic testing which can be declined without affecting
participation in the study. If agreement is given for this, 10mls of blood will be taken at
the end of the study and anonymously stored - any subsequent analysis of these samples will
be subject to approval of a Research Ethics Committee prior to analysis.
Adverse events Adverse events will be sought by symptom enquiry at each visit and by
monitoring of routine blood samples.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Completed |
NCT02832466 -
Quantifying the Deterioration of Physical Function in Renal Patients
|
N/A | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A |